Indications
Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Composition
- Active substance
- relugolix
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Orgovyx
- Active substance
- relugolix
- ATC code
- L02BX
- Therapeutic area
- Prostatic Neoplasms
- Marketing authorisation holder
- Accord Healthcare S.L.U.
- Status
- Authorised
- EU authorisation
- 29 Apr 2022